Yuki Saito: A pan-cancer landscape of driver alterations and their clinical actionability in Japanese patients

Yuki Saito, Postdoctoral researcher at Keisuke Kataoka Laboratory, shared a post by Keisuke Kataoka Laboratory on, X/Twitter adding:

“Happy to share our paper (my 1st paper as one of  corresponding authors) out in Cancer Discovery! Using >48,000 Japanese clinical sequencing data in CCAT,  we elucidated a pan-cancer landscape of driver alterations and their clinical actionability in Japanese patients.

Comparison with whites in AACR GENIE revealed higher TP53 mutation frequencies in Asians. Integration of CCAT, GENIE and TCGA revealed many co-occurring and exclusive relations between drivers, identifying co-occurrence of multiple mutations in epigenetic regulators.

More details in Keisuke Kataoka Laboratory threads. Kudos to amazing PhD student Sara Horie.”

Quoting Keisuke Kataoka Laboratory’s post:

“Excited to share our latest paper from Cancer Discovery. We used >48,000 samples from C-CAT, a real-world clinico-genomic database in Japan, to elucidate driver alterations and their clinical actionability in Japanese patients.”

Source: Yuki Saito/X and Keisuke Kataoka Laboratory/X